The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe
immunosuppression such as those with advanced HIV infection (ie AIDS) or those who have …

Drug-resistant microorganisms have become a major problem around the world. In
nosocomial and community settings, many important pathogens have demonstrated high …

Most ganciclovir (GCV)–resistant cytomegalovirus (CMV) isolates contain UL97 gene
mutations at codon 460 or 520 or between codons 590 and 607, where an increasing variety …

Cytomegalovirus (CMV) replicates rapidly in its human host with a doubling time of≈ 1 day.
Using simple mathematical models we show that the efficacy of the anti-CMV drug …

Abstract Ganciclovir-resistant (GanR) cytomegalovirus (CMV) is an emerging clinical
problem in organ transplant recipients, particularly recipients of kidney and pancreas and …

Renal transplant recipients are susceptible to infection by a wide array of pathogens.
Impaired inflammatory responses due to immunosuppressive therapies suppress clinical …

The development of cytomegalovirus (CMV) disease and subsequent emergence of drug-
resistant strains was examined in a large group of solid organ transplant recipients; drug …

Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in
allogeneic hematopoietic stem cell transplant recipients. The significant clinical impact of …

This review discusses the management of resistant cytomegalovirus and prevention
strategies for fatal therapy failures. Five drugs, ganciclovir/valganciclovir, cidofovir, foscarnet …